RPG
IMMU

Risk Paradigm Group’s Immunomedics Inc IMMU Stock Holding History

Risk Paradigm Group’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,000
Closed -$26.5K – 250
2017
Q2 		$26.5K Buy
+3,000
New +$21.1K 0.03% 178

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Risk Paradigm Group's IMMU Position: Q3 2017 in Review

Risk Paradigm Group sold out of Immunomedics Inc (IMMU) in Q3 2017, closing a stake of 3,000 shares — an estimated $26.5K sold.

Risk Paradigm Group first reported a position in IMMU in Q2 2017 and held it in 1 quarter. The position peaked at $26.5K in Q2 2017. 150 funds tracked by Wall St. Rank hold IMMU as of Q3 2017.

  • Risk Paradigm Group reported no remaining Immunomedics Inc position as of Q3 2017 after selling out during the quarter.
  • Risk Paradigm Group sold 3,000 Immunomedics Inc shares in Q3 2017, an estimated $26.5K.
  • Risk Paradigm Group first reported a position in Immunomedics Inc in Q2 2017 and held it in 1 quarter.
  • Risk Paradigm Group's Immunomedics Inc position peaked at $26.5K in Q2 2017.
  • 150 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2017.

Based on Risk Paradigm Group's 13F filing for Q3 2017, filed 8 Nov 2017.